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Abstract: 
Purpose: To evaluate the vascular endothelial growth factor (VEGF) plasma 
concentrations before and one, three and four weeks after intravitreal injection of 
bevacizumab or ranibizumab in patients with wet age-related macular degeneration 
(AMD). 
Methods: 12 patients with wet AMD and 18 controls were studied. 6 patients were 
treated with bevacizumab 1.25 mg and another 6 with ranibizumab 0.5 mg. Consecutive 
blood samples were taken before and one, three and four weeks after drug 
administration. Concentrations of VEGF in the plasma were measured by ELISA. 
Results: At baseline there were no significant differences regarding age or sex between 
controls, the bevacizumab and ranibizumab groups. The median VEGF concentrations 
were lower (p=0.004) in controls (180.0 pg/ml) than in the wet AMD group (281.2 
pg/ml). Consecutive VEGF concentrations decreased significantly at one (84,7 pg/ml; 
p<0.028), three (140,8 pg/ml p<0.028) and four (193,7 pg/ml p<0.028) weeks in the 
bevacizumab group. The same was verified in the ranibizumab group only after three 
(206,1 pg/ml p<0.028) and four (291,2 pg/ml p<0.046 ) weeks. 
Conclusions: Both bevacizumab and ranibizumab significantly decrease the systemic 
VEGF concentrations in the first four weeks after the start of the treatment. 
Bevacizumab seems to precipitate a more pronounced VEGF drop in the first week. On 
the contrary, ranibizumab has a more progressive reduction along the four weeks. 
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Introduction: 
 
Age-related macular degeneration (AMD) is the major cause of severe and irreversible vision 
loss in developed countries (Congdon 2004; Resnikoff et al. 2004). The exudative form of the 
disease (wet AMD) is characterized by choroidal neovascularization (CNV) that invades the 
subretinal space, and of its sequelae, with disrupting of the outer retinal layers resulting in 
scarring and vision loss (Bird et al. 1995). 
CNV is created, in response to metabolic distress, by the retinal pigment epithelium and the 
retina. Multiple molecular factors have been implicated in angiogenesis (Carmeliet 2003). 
These factors act through a variety of mechanisms to cause CNV. Vascular endothelial 
growth factor (VEGF)-A (VEGF hereafter) in particular has been extensively studied and 
plays a major role in mediating the development of eye diseases characterized by 
neovascularization (Aiello et al. 1994; Ferrara &  Kerbel 2005; Ng &  Adamis 2005). 
Therefore, a new class of antiangiogenic drugs that suppress VEGF has been introduced for 
the treatment of wet AMD (Gragoudas et al. 2004; Brown et al. 2006; Rosenfeld et al. 2006). 
Not long ago this condition was believed to be largely untreatable, but developments in the 
past few years have challenged this outlook. At present, the two pharmacologic therapies for 
wet AMD approved by the US Food and Drug Administration (FDA) and the European 
Medicines Agency (EMEA) are: pegaptanib sodium (Macugen®; Pfizer/Eyetech 
Pharmaceuticals, New York, NY, USA), a 28-base ribonucleic acid aptamer, wich binds and 
blocks the activity of extracellular VEGF-A, specifically the 165-amino-acid isoform 
(VEGF165) (Ruckman et al. 1998), and ranibizumab (Lucentis®; Novartis Pharma AG, Basel, 
Switzerland and Genentech Inc, South San Francisco, CA, USA), a recombinant humanized 
monoclonal antibody fragment that neutralizes all isoforms of VEGF and their biologically 
active degradation products (Ferrara et al. 2006). 
A third agent, bevacizumab (Avastin®; Genentech Inc), a recombinant humanized monoclonal 
neutralizing antibody against all isoforms of VEGF, approved for the systemic treatment of 
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many types of malignancy including colorectal cancer, non–small cell lung cancer, kidney 
cancer, breast cancer (only by the EMEA) and glioblastoma (only by the FDA), is now 
widely used off-label for the treatment of wet AMD (Carneiro et al. 2009; Brechner et al. 
2011). 
Although they differ in size, affinity for VEGF, intravitreal clearance speed (Bakri et al. 
2007a; Bakri et al. 2007b), and cost, both ranibizumab and bevacizumab bind the VEGF 
molecule at the same position. Ranibizumab, the approved treatment for wet AMD, costs 
approximately $1950 per dose, whereas bevacizumab, the off label treatment, costs 
approximately $30 (Jager et al. 2008). Because of the difference in cost, along with the 
similar perceived efficacy between these two drugs, bevacizumab has been broadly adopted 
(Rosenfeld 2006; Brechner et al. 2011). 
Whilst these new treatments are appropriately seen as important advances in wet AMD 
therapy, the long-term systemic safety of intravitreal anti-VEGF drugs remains uncertain. 
These drugs are administered by injection through the sclera into the vitreous cavity and 
despite the presence of the blood-retinal barrier, which shields the retina from the systemic 
blood circulation, systemic absorption occurs. Pharmacokinetic studies performed in rabbits 
and monkeys have showed that bevacizumab, and at a minor scale ranibizumab, can be 
detected in the serum after intravitreal injection (Gaudreault et al. 2005; Bakri et al. 2007a; 
Bakri et al. 2007b; Heiduschka et al. 2007). This is especially significant regarding the case of 
bevacizumab, which has been found to be associated with the development of hypertension 
and with an increased risk of venous thromboembolism, cardiac ischemia and arterial 
thromboembolic events in patients being treated for cancer (Kabbinavar et al. 2005; Nalluri et 
al. 2008; Ranpura et al. 2010). As for the ranibizumab treatment, no significant increase of 
nonocular adverse effects was found, although these studies were not designed or powered 
enough to detect small differences and only take in account a short period of time (Brown et 
al. 2006; Fung et al. 2006; Group 2011). Because intravitreal anti-VEGF treatment for wet 
AMD is given monthly (Brown et al. 2006; Rosenfeld et al. 2006) and is potentially required 
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for years, chronic VEGF inhibition may cause systemic adverse effects that are not promptly 
recognized. 
The detection of anti-VEGF molecules in the serum presents itself as challenging as there are 
no commercially available antibodies against bevacizumab or ranibizumab. For this reason 
we decided to measure the VEGF plasma concentrations using an ELISA technique. The 
purpose of this study is to determine the VEGF plasma concentrations in patients before and 
one, three and four weeks after an intravitreal injection of an anti-VEGF, either bevacizumab 
or ranibizumab. 
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Material and methods: 
 
Patients 
In the Department of Ophthalmology of Hospital São João, Porto, Portugal, treatment of wet 
AMD includes intravitreal injections of either ranibizumab or bevacizumab with follow-up 
visits and treatments in 4-weekly intervals. 
Ranibizumab (0.5mg) (Lucentis®) was approved in Portugal by INFARMED 
(http://www.infarmed.pt) for the treatment of wet AMD in 2008 and became available in 
Hospital São João in July of that year. It was subsequently used in all patients eligible for 
treatment. In 2011, the administration board of the hospital decided that all patients proposed 
to initiate treatment for wet AMD were to be asked to receive bevacizumab instead of 
ranibizumab. Patients that would accept this would be required to sign an informed consent. 
This change in the treatment protocol was introduced because of budget restrictions. Every 
other patient would be treated with ranibizumab. 
The study comparing the efficacy and safety of intravitreal anti-VEGF treatments in wet 
AMD, including VEGF blood level determination, was approved by the Ethics Committee of 
the Hospital São João, Portugal. Each patient signed an informed consent. The study was 
carried out in accordance with the tenets of the Declaration of Helsinki. 
12 patients were successfully selected for this study, 6 for the bevacizumab group and another 
6 for the ranibizumab group. 
Visual acuity of the patients included in this study was determined before the intravitreal 
administration of both anti-VEGF agents. Best-corrected visual acuity (BCVA) was 
established using Early Treatment Diabetic Retinopathy Study (ETDRS) charts. 
In total, four blood samples were collected: during preparation for the first intravitreal 
injection of an anti-VEGF (S0); one week ±1 day after the intravitreal injection (S1); three 
weeks ±1 day after the intravitreal injection (S2); and finally during preparation for the 
second intravitreal injection (S3), four weeks after the first one. 
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The first and the last blood samples (S0 and S3) were taken in the operating theatre before the 
intravitreal injection procedure. These injections were performed following a 3-day cycle of 
topical prophylactic ofloxacin. Cutaneous and conjuntival disinfection with iodopovidone was 
performed 5 minutes and immediately before the procedure. Ofloxacin was used again, 
topically, during 4 days after the procedure. Bevacizumab (Avastin® 100mg/4ml) was 
administered at a dose of 1.25mg (0.05 ml) by injection into the vitreous using a 30-gauge 
needle that was inserted 3.5-4.0 mm posterior to the limbus. Ranibizumab (Lucentis®) was 
administered at a dose of 0.5 mg (0.05 ml), using the same intravitreal injection technique. 
The second and third samples (S1 and S2) were collected at the outpatient clinic, in fasting 
patients, between 8 and 9 am. 
Wet AMD patients with concomitant chorioretinal diseases were excluded. 
Controls for this study were established from age and sex-matched patients from the 
Ophthalmology department that were scheduled for cataract surgery. Blood samples were 
obtained only once before the surgery. Their medical records were analysed looking for 
systemic and other ocular pathologies so that patients with AMD, diabetes, hypertension, 
vasoproliferative disorders or chorioretinal abnormalities were excluded. 
 
Blood samples preparation 
Blood samples were collected, consequently prepared by centrifugation at 2000g for 15 
minutes, the plasma isolated and then stored at -80ºC before use. 
 
ELISA assay 
The VEGF concentrations in the plasma were measured using a commercially available 
ELISA kit (Quantkine® Human VEGF ELISA Kit, R&D Systems Inc., Minneapolis, 
Minnesota, USA) in accordance with manufacturer’s instructions. Optical densities were 
measured at 450-570 nm with a microplate reader, and VEGF concentrations were calculated 
as protein-adjusted amount of VEGF, according to the standards used. 
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Statistical analysis 
Statistics were calculated using a commercially available software package (IBM SPSS 
Statistics 19; SPSS Inc, Chicago, Illinois, USA). In this study, data was considered not-
normally distributed, and was presented as median [interquartile range]. When comparing 
three groups, a Kruskal-Wallis test was performed, and in the case of comparing two groups, 
the Mann-Whitney U-test (for un-paired test) or the Wilcoxon matched pairs signed-rank test 
(for paired test) was employed. A p value <0.05 was accepted as significant. 
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Results: 
 
VEGF plasma concentrations were determined in 30 patients. Of these, 12 were patients with 
wet AMD (6 treated with ranibizumab and 6 treated with bevacizumab) and 18 were controls. 
Regarding VEGF plasma concentrations the 12 wet-AMD patients had significant (p=0.004 
un-paired test) higher values (281,2[197,6-594,9] pg/ml, median [interquartile range]) than 
the control group (181.0[67.0-219.0] pg/ml), see Table 1 and Fig. 1. 
At baseline (S0) there were no significant differences between the patients in the 
bevacizumab, ranibizumab and control groups with respect to age (p=0.462), and gender 
distribution (p=0.765), see Table 1 and Fig. 2. 
After one week ± 1 day (S1), VEGF levels were significantly lower in the bevacizumab group 
84,7[55,3-100,8] pg/ml comparing to the baseline (S0) samples 277,2[220,3-480,4] (p=0.028, 
paired test); they also decreased in the case of the ranibizumab patients group 334,7[163,3-
556,1] pg/ml when comparing with the respective S0 levels 412,2[155,7-627,6], however the 
difference was not significant (p=0.075). Three weeks ± 1 day after the intravitreal injection 
(S2) VEGF concentrations were again significantly decreased (p=0.028) in the bevacizumab 
group 140,8[72,8-330,4] pg/ml when comparing baseline (S0). The same happened with the 
ranibizumab group 206,1[72,0-342,2] pg/ml when relating to the respective S0 levels 
(p=0.028). Finally, 4 weeks after treatment (S3), VEGF sustained a significantly lower 
plasma level both in the bevacizumab group with 193,7[71,7-336,9] pg/ml (p=0.028) and in 
the ranibizumab group of patients with 291,2[142,2-393,5] pg/ml (p=0.046) when looking at 
the respective baseline (S0) levels. See Table 2 and Fig. 3. 
 
The concentration of serum VEGF was also analyzed between the two drugs at S1: 
bevacizumab 84,72[55,3-100,8] pg/ml and ranibizumab 334,7[163,3-556,1] pg/ml, wich are 
significantly different (p=0.025, un-paired test); S2: bevacizumab 140,8[72,8-330,4] pg/ml 
and ranibizumab 206,1[72,0-342,2] pg/ml, wich are not statistically different (p=0.631); and 
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S3: bevacizumab 193,7[71,7-336,9] pg/ml and ranibizumab 291,2[142,2-393,5] pg/ml, wich 
are also not significantly different (p=0.337). See Table 1. 
A reduction of VEGF plasma concentration was not verified in all patients: 1 of the 6 patients 
treated with ranibizumab did not present a lower VEGF level at S3 than at baseline (S0). 
Regarding the patients BCVA at baseline (S0), both the bevacizumab and ranibizumab 
showed no statistically significant differences (p=0.432): bevacizumab 64,5[22,2-73,0] 
ETDRS letters; and ranibizumab 43,5[29,2-62,7] ETDRS letters. See Fig. 4. 
Details on demographics, BCVA and VEGF concentrations are summarized in Table 1 and 2. 
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Discussion: 
 
Our study has shown that VEGF plasma concentrations decrease in the first weeks after 
intravitreal injection of anti-VEGF drugs. In bevacizumab treated patients the lowest levels 
are achieved in the first week (S1) and, in ranibizumab treated patients, in the second week 
(S2). At the end of 4 weeks (S3) the VEGF plasma concentrations were significantly reduced 
comparing to the baseline values. There were no statistically significant differences in the 
anti-VEGF treated group comparing with the control group at baseline (S0) regarding age, sex 
and visual acuity, though baseline VEGF serum levels were higher in the wet-AMD group 
than in controls. 
Normal vascular growth is a complex process involving sequential events and many ligand–
receptor interactions (Ferrara et al. 2003). VEGF activity often corresponds to a rate-limiting 
step in normal vascular growth and also takes on a critical role in pathological angiogenesis, 
which is required for tumor growth and metastatic spread (Ferrara &  Alitalo 1999; Rugo 
2004). In Ophthalmology, the importance of VEGF originates from the fact that this molecule 
is a major mediator of neovascularization related to various intraocular disorders, including 
ischemic retinal diseases and wet AMD (Adamis &  Shima 2005). Because of this, it becomes 
essential to analyze the systemic effects of both bevacizumab and ranibizumab anti-VEGF 
intravitreal therapies. 
Several pharmacokinetic studies performed in rabbits and monkeys have showed that 
bevacizumab, and at a minor scale ranibizumab, can be detected in the serum after intravitreal 
injection (Gaudreault et al. 2005; Bakri et al. 2007a; Bakri et al. 2007b; Heiduschka et al. 
2007). In particular, Nomoto et. al showed in a rabbit model, that intravitreal injections of 
bevacizumab resulted in high concentrations of this drug in the serum, and that bevacizumab 
was distributed into the intraocular tissues in fellow eyes via systemic circulation at a level 
which may be effective in blocking VEGF activity (Nomoto et al. 2009).  
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Matsuyama et al. showed decreased plasma levels of VEGF in patients with proliferative 
diabetic retinopathy being treated with intravitreal bevacizumab, and hinted that this antibody 
enters the general circulation (Matsuyama et al. 2010). Another study executed in infants with 
retinopathy of prematurity revealed results that indicate that bevacizumab can escape from the 
eye into the systemic circulation (Sato et al. 2012). However, in these two pathologies, which 
are characterized by retinal neovascularization, the new vessels are in close contact with the 
vitreous cavity, this way more readily facilitating diffusion of the drugs to the systemic 
circulation. In the particular case of wet AMD the newly formed blood vessels are located in 
the sub-retinal space or below the retinal pigment epithelium, which may make it harder to let 
the anti-VEGF drugs travel to the general circulation through the incompetent walls of the 
new vessels. 
Carneiro et al. found that intravitreal bevacizumab significantly reduced plasma VEGF, 28 
days after three initial consecutive intravitreal injections, in patients with wet AMD, though it 
could not confirm the same findings with ranibizumab (Carneiro et al. 2012). 
To the best of our knowledge data have not been published to determine and compare the 
blood concentrations of VEGF after intravitreal injection of either bevacizumab or 
ranibizumab in a series of patients with wet AMD, specifically until the fourth week after 
treatment initiation. Hence, this paper aims to analyze the systemic levels of VEGF in wet 
AMD patients treated with intravitreal bevacizumab or ranibizumab. The sample collection 
took place in the first, second, and fourth weeks after therapy start, and data was then 
compared between the two drugs. 
This study found statistically significant higher plasma levels of VEGF in patients with wet 
AMD as compared with controls. This goes accordingly with the data reported by Tsai et al. 
in a series of 42 patients with active AMD/CNV (Tsai et al. 2006) but contrary to what 
Carneiro et al. published in a study with 43 wet AMD patients (Carneiro et al. 2012). Our data 
is supported by the fact that wet-AMD is a disease characterized by neovascular proliferation, 
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for which VEGF is a key agent (Jager et al. 2008). This could explain why baseline VEGF 
would be higher in this group. On the other hand, the population chosen for this study 
approaches that one used by Carneiro et al., so our small sample size could be in the origin of 
this difference (Carneiro et al. 2012). 
Regarding the first week after the intravitreal injection (S1), VEGF concentrations are only 
substantially decreased comparing to the baseline (S0) in the group of patients treated with 
bevacizumab. 
Bevacizumab, has been found in prior studies about diabetic retinopathy (Matsuyama et al. 
2010) and retinopathy of prematurity (Sato et al. 2012) to decrease systemic VEGF 1 week 
after administration, which is line with our results. This is further reinforced by bevacizumab 
pharmacokinetic studies in rabbits (Bakri et al. 2007b; Nomoto et al. 2009) and monkeys 
(Heiduschka et al. 2007; Miyake et al. 2010) that found that bevacizumab is detected in the 
general circulation one week after intraocular administration. Miyake et al., in particular, 
reported a serum concentration of 1430 ± 186 ng/ml (Miyake et al. 2010). Results in in vitro 
studies have suggested that a molar ratio of 2.6 to 1 of bevacizumab to VEGF165 is necessary 
for maximum inhibition of endothelial proliferation. The half-maximum inhibitory 
concentration of bevacizumab is 22 ng/ml, and the minimum concentration that completely 
blocks VEGF activity including endothelial cell growth, migration, and hyperpermeability is 
500 ng/ml (Wang et al. 2004). This could raise the conclusion that, by its pharmacokinetics, 
bevacizumab is indeed present in the general circulation at concentrations well above the 
necessary to effectively suppress VEGF activity. 
On the other hand, studies in rabbits (Bakri et al. 2007a) and in monkeys (Gaudreault et al. 
2005) have reported that ranibizumab is, respectively, either undetectable or at very low 
concentrations in the serum after intravitreal administration. So, we would expect that VEGF 
levels would not drop significantly. Notwithstanding the concentration drop we witnessed 
was mild, and to our knowledge there are no studies published with VEGF serum levels after 
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ranibizumab intraocular administration in the first week. 
Three weeks after the intravitreal administration of the anti-VEGF drugs (S2), serum VEGF 
concentrations were decreased significantly. This was the case in both drugs. Again, like for 
the measurements made at 1 week (S1), no studies have been reported for the VEGF serum 
concentrations three weeks after an intravitreal treatment (S2). 
Finally, at 4 weeks after intravitreal administration (S3), both bevacizumab and ranibizumab 
group have a significantly decreased level of VEGF in the serum comparing to baseline (S0). 
Minding previous studies, this decrease was expected in the bevacizumab group (Matsuyama 
et al. 2010). It seems that bevacizumab can still effectively inhibit systemic VEGF levels one 
month after an intraocular 1.25 mg (0.05ml) injection. In the ranibizumab group we could not 
compare our values with any particular study, as there are no published papers with this 
specific information. One could, though, relate to the results from various rabbit and monkey 
models. These state that at 4 weeks after administration no ranibizumab can be detected in the 
serum, and therefore no significant VEGF inhibition would be expected. Carneiro et al., 
analyzed VEGF systemic levels 28 days after a loading dose of ranibizumab, which put the 
patients under an even more sustained VEGF suppression than in this work, also did not see a 
statistically significant decrease in VEGF (Carneiro et al. 2012). In our study we saw a 
substantial drop in the ranibizumab group. This could be consequence from some limitations 
of our study, like the low number of patients that were included in the assay. A larger sample 
would give this study more statistical power. 
There has been some debate as to which level does bevacizumab and ranibizumab surpass the 
blood-retinal barrier when injected into the vitreous cavity. 
Various studies have approached the systemic repercussions of intravitreal anti-VEGF 
treatments in humans (Sawada et al. 2007; Matsuyama et al. 2009; Carneiro et al. 2012; Sato 
et al. 2012). 
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Matsuyama et al. showed decreased plasma levels of VEGF in patients with proliferative 
diabetic retinopathy being treated with intravitreal bevacizumab, and hinted that bevacizumab 
enters the general circulation (Matsuyama et al. 2010). Another study executed in infants with 
retinopathy of prematurity revealed that the bevacizumab molecule can escape from the eye 
into the systemic circulation, as its presence was confirmed and measured in the serum (Sato 
et al. 2012). 
Carneiro et al. found that intravitreal bevacizumab significantly reduced plasma VEGF 28 
days after an intravitreal injection in patients with wet AMD, though it could not confirm the 
same findings with ranibizumab. (Carneiro et al. 2012) 
Since the inner ocular tissues in the blood-ocular barrier is separated from the blood system 
(Cunha-vaz 1997) one would not expect to detect a full-length antibody in the blood system 
only a short time after intravitreous injection. However, as explored previously, recent 
pharmacokinetics data from monkeys and humans all indicate that intravitreous bevacizumab 
appears in the blood within hours after intravitreous injection. It has been demonstrated that 
the neonatal Fc receptor (FcRn) is present in several different ocular tissues including the 
blood-retinal barrier in the rodent eye (Kim et al. 2008). The expression of FcRn receptor at 
the blood-ocular barrier suggests transportation of IgG across complex tight junctions in the 
eye may occur via FcRn-mediated transcytosis. This could help to explain why bevacizumab 
is so readily transported to the general circulation, implicating a decrease of systemic VEGF 
activity. 
A comparative study of bevacizumab and ranibizumab using human microvascular 
endothelial cells showed that although both agents inhibited angiogenesis, a more solid down-
regulation of VEGFR2 was obtained with bevacizumab comparing to ranibizumab (Costa et 
al. 2009). Regardless both agents presented anti-angiogenic actions, distinct effects were 
exerted by the two molecules resulting in different cell behaviors. Ranibizumab, due to the 
absence of an Fc portion, is much more rapidly degraded than bevacizumab. Conversely, the 
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full antibody characteristics of latter render this molecule a much more stable half-life, which 
probably results in longer clinical effects. 
Systemic intravenous bevacizumab therapy has been associated with increased risk of 
hypertension, venous thromboembolism, cardiac ischemia and arterial thromboembolic events 
in patients being treated for cancer (Kabbinavar et al. 2005; Nalluri et al. 2008; Ranpura et al. 
2010). The dose used for intravitreal administration of anti-VEGF therapy is much less than 
that used intravenously, and the injection target is an intraocular site rather than blood vessels. 
Therefore, systemic effects caused by intravitreal treatments are considered to be much less 
significant. However, not only the potential ocular adverse events (Avery et al. 2006; Fung et 
al. 2006; Meyer et al. 2006; Wu et al. 2008) but also the possible drug related systemic effects 
have been reported recently (Fung et al. 2006; Shima et al. 2008; Wu et al. 2008; Carneiro et 
al. 2011). The sustained reduction in systemic VEGF concentrations in an older population 
group, such as the wet AMD patients, with all its inherent co-morbidities, raises concerns 
about the long-term effects o this kind of therapy. This seems to be of heavier preponderance 
when talking about bevacizumab, as it has been found to decrease more sustainably the serum 
VEGF levels, than with the case of ranibizumab (Carneiro et al. 2012). 
In conclusion, with this study we found that both bevacizumab and ranibizumab significantly 
constrain the systemic VEGF in the first four weeks after the start of the treatment, and also 
that bevacizumab seems to precipitate a more pronounced VEGF drop in the first week, 
contrary to ranibizumab that has a more progressive reduction along the four weeks. 
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Tables: 
 
Table 1. Demographic, best corrected visual acuity (BCVA) and vascular endothelial growth 
factor (VEGF) data obtained from the three groups. 
 
 The groups are comparable with respect to age and gender. The S0 (baseline) plasma levels 
of VEGF are significantly increased in the wet age-related macular degeneration group, 
treated with either bevacizumab or ranibizumab, when comparing to the control group. VEGF 
levels decrease achieving their lowest concentrations at S1 (one week) in the case of 
bevacizumab and S2 (three weeks) in the case of ranibizumab. There are only significant 
VEGF differences between bevacizumab and ranibizumab groups at S1. At S2 and S3 (four 
weeks) the differences are not substantial. 
Not-normally distributed values are presented as median and the interquartile range 
(median[interquartile range]). F, female. M, male. 
 
 
 
 
 
 
 Bevacizumab Ranibizumab Control p-value 
Age (years) 70.5[63.0-79.5] 78.0[68.8-89.0] 74.0[68.8-86.8] 0.463 
Gender (F/M) 2:4 3:3 9:9 0.765 
BCVA (S0) 
(letters) 64,5[22,2-73,0] 43,5[29,2-62,7] - 0.432 
VEGF S0 (pg/ml) 281,2[197,6-594,9] 180.0[65.5-224.0] 0.004 
VEGF S0 (pg/ml) 277,2[220,3-480,4] 412,2[155,7-627,6] - - 
VEGF S1 (pg/ml) 84,7[55,3-100,8] 334,7[163,3-556,1] - 0.025 
VEGF S2 (pg/ml) 140,8[72,8-330,4] 206,1[72,0-342,2] - 0.631 
VEGF S3 (pg/ml) 193,7[71,9-336,9] 291,2[142,2-393,5] - 0.337 
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Table 2. Consecutive vascular endothelial growth factor (VEGF) plasma concentrations. 
 
 
 
 
All the bevacizumab VEGF values in the following one (S1), three (S2) and four (S3) weeks 
are statistically lower than the baseline (S0). In the ranibizumab group we only start to see a 
substantial decrease of VEGF concentrations at S2 and S3. 
Not-normally distributed values are presented as median and the interquartile range 
(median[interquartile range]). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 VEGF S0 (pg/ml)  VEGF (pg/ml) p-value 
Bevacizumab 277,22[220,25-480,43] 
S1: 84,72[55,25-100,79] 0.028 
S2: 140,79[72,75-330,43] 0.028 
S3: 193,65[71,68-336,86] 0.028 
Ranibizumab 412,20[155,68-627,58] 
S1: 334,72[163,28-556,10] 0.075 
S2: 206,14[72,04-342,21] 0.028 
S3: 291,15[142,23-393,47] 0.046 
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Ilustrations and graphics: 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Vascular endothelial growth factor (VEGF) plasma levels at baseline (S0). Wet age-
related macular degeneration (AMD) patients have substantially higher VEGF plasma 
concentrations. The horizontal bars represent the interquartile range. * = p<0.05. 
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Fig. 2. The distribution of age among the three groups. The circle and the square represent the 
median; the bars represent the interquartile range. There are no statistically significant 
differences between groups. 
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Fig. 3. Plasma vascular endothelial growth factor (VEGF) concentrations at baseline (S0), 
one (S1), three (S2) and four (S3) weeks after the intravitreal administration of both 
bevacizumab and ranibizumab groups. In the bevacizumab group S1, S2 and S3 consecutive 
VEGF levels are significantly decreased comparing to S0. In the ranibizumab group only at 
S2 and S3 we found a substantial reduction of VEGF concentrations comparing to baseline. 
The circle and the square represent the median; the bars represent the interquartile range; b = 
p<0.05 in the bevacizumab group; r = p<0.05 in the ranibizumab group. 
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Fig. 4. The visual acuities at baseline for the bevacizumab and ranibizumab group. The 
circule and the square represent the median; the bars represent the interquartile range. There 
are no statistically significant differences between groups. 	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